Biogen Inc. said Alfred Sandrock Jr., its chief medical officer, will also take on the role of executive vice president for research and development for the company, effective Oct. 1.
The previous executive vice president for research and development, Michael Ehlers, stepped down and will leave the company effective Oct. 11 to pursue a new career opportunity.
Sandrock, who has been the company's chief medical officer since 2012, joined the company in 1998. He has been on the executive committee since 2015 and has held several senior executive positions, including senior vice president of development sciences and of neurology research and development.
The Cambridge, Mass.-based company also appointed Alphonse Galdes as executive vice president for pharmaceutical operations and technology, effective Oct. 1.
Galdes joined the company in 1995 and has served on the executive committee of the company since September. He has held several senior executive positions including senior vice president for asset development and portfolio management from November 2015 to September 2019.
Biogen develops and manufactures therapies for treating neurological and neurodegenerative diseases worldwide.
